Erschienen in:
22.05.2023 | Invited Commentary
Statins in Cirrhosis: Trial Data Are in but the Jury Is Still Out
verfasst von:
David E. Kaplan
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 8/2023
Einloggen, um Zugang zu erhalten
Excerpt
Hepatic decompensation, particularly when complicated by the development of ascites and/or variceal hemorrhage, demarcates an inflection point in the natural history of advanced chronic liver disease (ACLD). Although patients who maintain compensated status (cACLD) generally maintain near-normal life expectancy, patients with decompensated (dACLD) progress rapidly to liver transplantation or death within 1–3 years [
1]. The presence of clinically significant portal hypertension, defined by a hepatic vein wedge pressure gradient ≥ 10 mmHg or estimated by non-invasive assessments, such as platelet count or liver stiffness measurements by elastography, remains the primary risk factor for incident hepatic decompensation [
2]. Medical lowering portal pressure, primarily through the use of non-selective beta-blockers, reduces the risk of incident decompensation, improving long-term outcomes [
3]. …
